10-K: Sharps Technology Reports FY24 Results, Navigates Financial Challenges and Sets Stage for Potential Revenue in 2025

Sharps Technology reports a net loss for FY24, focuses on expanding production capacity, and anticipates potential revenue generation in the second half of 2025.

Summary

• Sharps Technology, Inc. reported a net loss of $9.3 million for the year ended December 31, 2024, compared to a net loss of $9.8 million in the previous year.
• The company has not generated any revenue to date but anticipates potential revenue generation in the second half of 2025.
• Research and development expenses increased to $2.5 million, primarily due to asset machinery impairments.
• General and administrative expenses decreased to $7.2 million, mainly due to lower marketing and public company costs.
• Net interest expense was $1.7 million, driven by accreted interest on debt financing.
• The company forfeited a $1 million escrow deposit related to a terminated asset acquisition agreement.
• Sharps Technology completed a $20 million offering in January 2025 to expand operations and become debt-free.
• The company is focused on driving revenue growth from Securegard and Sologard projects in 2025 and securing manufacturing capacity for next-generation prefillable syringes.
• Production is currently on track, with the Company preparing for a potential transition to revenue in the second half of 2025, subject to the successful execution of its plans.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured funding and is preparing for potential revenue generation, it is currently operating at a loss and faces significant financial challenges and legal uncertainties. The sentiment is cautiously optimistic but tempered by the company's current financial situation.

Positives

• The company completed a $20 million offering in January 2025, strengthening its financial position.
• General and administrative expenses decreased by $1.4 million, indicating improved cost management.
• The company is focused on expanding production capacity in Hungary to meet increasing demand.
• Sharps Technology is actively working to secure manufacturing capacity for its next-generation polymer-based prefillable syringes.
• The company is preparing for a potential transition to revenue in the second half of 2025, subject to the successful execution of its plans.

Negatives

• The company reported a net loss of $9.3 million for the year ended December 31, 2024.
• Sharps Technology has not generated any revenue to date.
• The company forfeited a $1 million escrow deposit related to a terminated asset acquisition agreement.
• The company has a working capital deficit of $2.0 million as of December 31, 2024.
• The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement.

Risks

• The company's ability to generate revenue and achieve profitability is uncertain.
• The company faces potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.
• The company is involved in ongoing legal proceedings, which could result in significant expenses.
• The company's success depends on the quality, reliability, and safety of its products, and defects could damage its reputation.
• The company may not be able to raise capital as needed to develop its products or maintain its operations.

Future Outlook

The company anticipates potential revenue generation in the second half of 2025 and is focused on driving revenue growth from Securegard and Sologard projects. Sharps is also working to secure manufacturing capacity for its next-generation polymer-based prefillable syringes.

Management Comments

• Sharps is committed to advancing innovation in the syringe space and we continue to collaborate with both government and private investment sources in Hungary to increase our manufacturing footprint and meet the escalating demand for Sharps Securegard and Sologard syringes.
• With the recent financing secured, the Company believes that it is positioned to advance its growth strategy by utilizing new working capital to support essential operating expenses.

Industry Context

The report highlights the growing demand for innovative injection solutions, particularly in areas like vaccines, biologics, weight loss (GLP-1), ophthalmic and cosmetic applications, gene therapies, and diabetes and inflammatory disease management. This aligns with the broader industry trend of increasing reliance on injectable therapies.

Comparison to Industry Standards

• The report mentions competitors such as Retractable Technologies, Inc., Becton Dickinson & Company, Medtronic Minimally Invasive Therapies, Terumo Medical Corp., Smiths Medical, and B. Braun.
• Sharps aims to compete on healthcare worker and patient safety, product performance, and quality, emphasizing its innovative drug delivery systems with active and passive safety features, as well as ultra-low waste features.
• The company's disposable syringe lines carry less than 20 microliters of dead space, compared to the 70 microliters Low Dead Space designation and the up to 140 microliters dead space found in competitors syringes.

Legal Proceedings

• Barry Berler commenced a lawsuit against the Company for alleged failure to make full payment of certain monthly payments under his consulting agreement, failure to pay a bonus, and a declaration and injunctive relief establishing that Berler is the rightful owner of 50% of the Company's Series A Preferred Stock.
• Barry Berler filed a demand for arbitration and statement of claim under the commercial arbitration rules of the American Arbitration Association (AAA) asserting claims for payment of $500,000 plus interest, under the Company's royalty agreement with Berler, as amended, rescission thereof and reversion to Berler of the intellectual property rights subject thereto.
• Plastomold commenced a lawsuit against the Company for alleged failure to pay invoices, breach of the implied covenant of good faith and fair dealing, unjust enrichment, and conversion.

Related Party Transactions

• As of December 31, 2024 and 2023, accounts payable and accrued liabilities include $99,500 and $32,974, respectively, payable to officers, and directors of the Company.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and dilution from future equity issuances.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers may benefit from the company's innovative safety syringe products, but the availability of these products depends on the company's ability to secure manufacturing capacity and generate revenue.
• Suppliers may be impacted by the company's financial challenges and potential changes in its business strategy.

Next Steps

• Expand operations in Europe by adding advanced machinery, expanding the workforce, and enhancing production capabilities.
• Drive revenue growth from both the Securegard and Sologard projects in 2025.
• Secure manufacturing capacity for the company's next-generation polymer-based prefillable syringes.
• Continue to monitor the closing bid price of its Common Stock and will consider its available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement within the allotted compliance period.

Key Dates

Keywords

Sharps Technology, safety syringes, financial results, revenue, net loss, manufacturing, offering, warrants, debt, Nasdaq, legal proceedings, risk factors